Exclusive: Novo Nordisk cuts hit production line jobs at key US plant, posts show

Group 1 - Novo Nordisk has laid off dozens of employees at its largest U.S. manufacturing site for obesity and diabetes drugs, indicating potential operational challenges [1] - The layoffs are seen as a signal of shifting market dynamics and possibly reduced demand for its blockbuster drugs [1] - The company is facing increased competition in the obesity and diabetes treatment market, which may impact its future growth prospects [1]